A diversity-oriented synthesis strategy enabling the combinatorial-type variation of macrocyclic peptidomimetic scaffolds
作者:Albert Isidro-Llobet、Kathy Hadje Georgiou、Warren R. J. D. Galloway、Elisa Giacomini、Mette R. Hansen、Gabriela Méndez-Abt、Yaw Sing Tan、Laura Carro、Hannah F. Sore、David R. Spring
DOI:10.1039/c5ob00371g
日期:——
demonstrated by the step-efficient synthesis of a structurally diverse library of over 200 macrocyclic peptidomimetic compounds, each based around a distinct molecular scaffold and isolated in milligram quantities, from readily available building-blocks. To the best of our knowledge this represents an unprecedented level of scaffold diversity in a synthetically derived library of macrocyclic peptidomimetics
大环肽模拟物与广泛的生物活性有关。然而,尽管具有这些潜在有价值的特性,但大环肽模拟结构类别通常被认为在药物发现中探索不足。这归因于缺乏生产具有高水平结构和形状多样性的大环肽模拟物集合的通用方法。特别是,目前的大环肽模拟库缺乏支架多样性;事实上,多种分子支架的有效构建对合成化学家提出了巨大的普遍挑战。这里我们描述一个新的,大环肽模拟物的多样性导向合成(DOS)的先进策略,能够实现分子支架(核心大环结构)的组合变化。这种 DOS 策略的普遍性和稳健性通过逐步有效地合成结构多样的 200 多种大环肽模拟化合物库来证明,每种化合物都基于不同的分子支架,并从现成的构建块中分离出来,并以毫克的数量分离。据我们所知,这代表了合成衍生的大环肽模拟物文库中前所未有的支架多样性水平。化学信息学分析表明,库化合物进入的化学空间区域与最畅销的品牌药物和大环天然产品所涉及的区域不同,说明我们的 DOS 方法对当前药
[EN] OPTICAL PROBE FOR THROMBIN<br/>[FR] SONDE OPTIQUE POUR THROMBINE
申请人:UNIV COURT UNIV OF EDINBURGH
公开号:WO2016151297A1
公开(公告)日:2016-09-29
Optical probes are presented, the probes comprising a first probe element, and a second probe element connected to a core. The first probe element comprises a first fluorophore connected to a first quencher by a first cleavable linker. The second probe element comprises a second fluorophore connected to a second quencher by a second cleavable linker. The first fluorophore is separated from the first quencher when the first cleavable linker is cleaved, and the second fluorophore is separated from the second quencher when the second cleavable linker is cleaved. Methods of detecting a first and second enzyme using the optical probe are also presented.
The invention relates to a method of making a polypeptide comprising an orthogonal functional group, said orthogonal functional group being comprised by an aliphatic amino acid or amino acid derivative, said method comprising providing a host cell; providing a nucleic acid encoding the polypeptide of interest; providing a tRNA-tRNA synthetase pair orthogonal to said host cell; adding an amino acid or amino acid derivative comprising the orthogonal functional group of interest, wherein said amino acid or amino acid derivative is a substrate for said orthogonal tRNA synthetase, wherein said amino acid or amino acid derivative has an aliphatic carbon backbone; and incubating to allow incorporation of said amino acid or amino acid derivative into the polypeptide of interest via the orthogonal tRNA-tRNA synthetase pair. The invention also relates to certain amino acids, and to polypeptides comprising same.
Genetic Encoding and Labeling of Aliphatic Azides and Alkynes in Recombinant Proteins <i>via</i> a Pyrrolysyl-tRNA Synthetase/tRNA<sub>CUA</sub> Pair and Click Chemistry
作者:Duy P. Nguyen、Hrvoje Lusic、Heinz Neumann、Prashant B. Kapadnis、Alexander Deiters、Jason W. Chin
DOI:10.1021/ja900553w
日期:2009.7.1
recombinant proteins in Escherichia coli. Proteins containing the alkyne functional group are labeled with an azido biotin and an azido fluorophore, via copper catalyzed [3+2] cycloaddition reactions, to produce the corresponding triazoles in good yield. The methods reported are useful for the site-specific labeling of recombinant proteins and may be combined with mutually orthogonal methods of introducing
Trifunctional Dibromomaleimide Reagents Built Around A Lysine Scaffold Deliver Site‐selective Dual‐modality Antibody Conjugation
作者:Yanbo Zhao、Vijay Chudasama、James R. Baker
DOI:10.1002/cbic.202300356
日期:2023.9.15
We demonstrate a rapid reduction-bridging-double click sequence to yield dual-modality antibody conjugates using aryl selenols as novel disulfide reducing reagents and trifunctional dibromomaleimides (DBMs) as bridging reagents. This work will provide more possibilities for the development of multi-functionalised antibody drug conjugates (ADCs).